Loading market dashboard
BioNTech SE
BNTXHealthcareNASDAQDE
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).
Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.
MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly.
BioNTech NASDAQ: BNTX used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network.
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.
BioNTech SE is downgraded to Sell due to declining COVID vaccine revenues, leadership exits, and pipeline uncertainty. BNTX faces €531.9m Q1 net loss, expects €2–3bn 2026 revenues, and plans €1bn share buyback amid €16.8bn cash reserves. Major staff cuts and site exits are underway, targeting €500m annual savings to support the oncology pivot.
A German government spokesperson said on Wednesday that the loss of BioNTech vaccine production in the country can be offset by other companies.
BioNTech SE (BNTX) Q1 2026 Earnings Call Transcript
Shares of BioNTech SE (NASDAQ:BNTX) are trading lower on Tuesday as the company reported mixed first-quarter financial results.
The company said it would exit operations at some manufacturing plants in Germany and Singapore, as well as sites it acquired as part of its CureVac takeover.
Germany's BioNTech said on Tuesday it would close sites affecting up to 1,860 jobs and buy back up to $1 billion worth of its shares, following the announcement of two co-founders quitting the COVID-19 vaccine maker.
BioNTech SE (Nasdaq: BNTX) today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.
Top insights from the latest market news from Thursday, April 23, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Results from two early-stage trials offer new hope for a cancer that kills around one in eight patients within five years.
MAINZ, Germany, April 21, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2026 on Tuesday, May 5, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link. Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company's website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company's website for 30 days following the call.
Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
Freestone Capital Holdings LLC acquired a new stake in BioNTech SE Sponsored ADR (NASDAQ: BNTX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,914 shares of the company's stock, valued at approximately $753,000. A number of other hedge
BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.
Vaccine makers Pfizer and BioNTech have halted recruitment for a large U.S. trial of their updated COVID-19 vaccine in healthy adults aged 50 to 64, saying enrollment in the trials had been too low to generate the needed data.
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
MAINZ, Germany, March 24, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data from its diversified portfolio in the field of lung cancer at the European Lung Cancer Congress (“ELCC”) held in Copenhagen, Denmark, from March 25-28, 2026. The data updates covered in both oral and poster presentations highlight progress across late-stage immunomodulator candidates pumitamig and gotistobart, as well as antibody-drug conjugate (“ADC”) programs, across various lung cancer subtypes and lines of treatment. BioNTech's clinical portfolio encompasses both monotherapies and combinations with standard of care treatments, as well as novel-novel combination regimens aimed at delivering differentiated therapeutic profiles for the treatment of patients with lung cancer across all stages of the disease.
The first severe case of the virus has been detected in New York.
BioNTech (BNTX) reported upbeat Q4 results and FY26 sales guidance below estimates. Shares gained 7.7% on Wednesday. Analysts have mixed opinions.
On March 10, 2026, Oracle outperformed in after-hours trading and oil prices fell in a volatile, energy-driven session.
BioNTech SE (BNTX) Q4 2025 Earnings Call Transcript
Stock News U.S. pump prices jump on war-driven supply shock: Average U.S. gasoline rose to about $3.54/gal, the highest since midâ2024, as the U.S.âIran con
The company guided 2026 total revenue to roughly $2.2–$2.5 billion, below Street expectations, stating that Covid will be a smaller contributor going forward and growth will depend increasingly on the oncology pipeline.
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of BioNTech SE (NASDAQ: BNTX). The investigation focuses on BioNTech's executive officers and whether investor losses may be recovered under federal securities laws.
BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and Ozlem Tureci (CMO), said they would depart to set up a new biotech firm at the end of 2026.
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology. BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties.
German biopharma outfit BioNTech SE reported lackluster fiscal Q4 results on Tuesday. Guidance for the year now underway is just as disappointing.
The Dow and Nasdaq are sporting triple-digit leads this afternoon as oil prices take a breather
Regan Capital chief investment officer Skyler Weinand talked with Proactive's Stephen Gunnion about how rising interest rates, inflation, and global...
With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA...
The company's co-founders said they are leaving to start a new mRNA-based company.
Vertex pops on fast-track chances, Oracle leads notable Tuesday earnings, and more
The German biotech provides a weak full-year outlook and announces the exit of its co-founders.
374Water Inc (NASDAQ:SCWO, FRA:8LL) announced that it has received approval from the City of Orlando to provide waste destruction services at the Iron...
The company said its cofounders were leaving to form a biotechnology startup focused on developing messenger RNA.
The cofounders of BioNTech , Ugur Sahin and Oezlem Tuereci, will leave the COVID-19 vaccine maker by the end of 2026 to set up their own new company, the biotech firm said on Tuesday.
BioNTech on track for a catalyst-rich year with six late-stage data readouts expected across immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies Increased focus on PD-L11/VEGF-A bispecific immunomodulator pumitamig with e ight global Phase 3 clinical trials planned to be ongoing for year-end in collaboration with Bristol Myers Squibb Full year 2025 revenues of €2.9 billion 2 , net loss of €1.1 billion (adjusted3 net loss of €0.1 billion) and diluted loss per share of €4.70 ($5.31 4 ) (adjusted3 diluted loss per share of €0.48 ($0.55 4 )) Strong financial position continues to de-risk execution with cash, cash equivalents and security investments of €17.2 billion5 Expect 2026 total revenues of €2.0 billion to €2.3 billion, adjusted3 R&D expenses between €2.2-2.5 billion and adjusted3 SG&A expenses7 between €700-800 million BioNTech co-founders Ugur Sahin and Özlem Türeci to establish an independent company with a focus on next-generation mRNA innovations; management transition by end of 2026 Conference call and webcast scheduled for March 10, 2026, at 8:00 a.m. EDT (1:00 p.m.
Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options, will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
